Pavimol Angsantikul is a pharmaceutical development scientist and principal investigator in the Angsantikul laboratory for translational research. The Angsantikul laboratory is conducting preclinical and early clinical formulation and manufacturing process design of oral, topical, implantable, or injectable dosage forms of novel sexual and reproductive health interventions in the CBR pipeline.
Angsantikul’s research interest is in the area of drug delivery. Her biological knowledge and expertise in nanoengineering has led to the development of bioinspired and translational platforms, including natural cell-mimicking nanoparticles for targeted antibiotic delivery; cell receptor-functionalized nanoparticles for bacterial toxin neutralization; active micromotor-enabled oral drug delivery; and nanoparticle-hydrogel hybrid system for topical delivery.
Before joining the Council, Angsantikul completed a postdoctoral fellowship with Prof. Samir Mitragotri at the School of Engineering and Applied Science and the Wyss Institute for Biologically Inspired Engineering at Harvard University. Her postdoctoral research on oral delivery of biologics has informed development of an invention, which is being filed for patent.
Angsantikul has authored and co-authored more than 30 publications appearing in high-impact peer-reviewed journals. She holds a BEng in nanoengineering from Chulalongkorn University, Thailand, where she graduated first in her class, and a PhD in nanoengineering from the University of California, San Diego.